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Abstract
Introduction: HIV-positive patients receiving combination antiretroviral therapy (cART) frequently experience metabolic
complications such as dyslipidemia and insulin resistance, as well as lipodystrophy, increasing the risk of cardiovascular disease
(CVD) and diabetes mellitus (DM). Rates of DM and other glucose-associated disorders among HIV-positive patients have been
reported to range between 2 and 14%, and in an ageing HIV-positive population, the prevalence of DM is expected to continue
to increase. This study aims to develop a model to predict the short-term (six-month) risk of DM in HIV-positive populations and
to compare the existing models developed in the general population.
Methods: All patients recruited to the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study with follow-up data,
without prior DM, myocardial infarction or other CVD events and with a complete DM risk factor profile were included.
Conventional risk factors identified in the general population as well as key HIV-related factors were assessed using Poisson-
regression methods. Expected probabilities of DM events were also determined based on the Framingham Offspring Study DM
equation. The D:A:D and Framingham equations were then assessed using an internal-external validation process; area under
the receiver operating characteristic (AUROC) curve and predicted DM events were determined.
Results: Of 33,308 patients, 16,632 (50%) patients were included, with 376 cases of new onset DM during 89,469 person-years
(PY). Factors predictive of DM included higher glucose, body mass index (BMI) and triglyceride levels, and older age. Among
HIV-related factors, recent CD4 counts ofB200 cells/mL and lipodystrophy were predictive of new onset DM. The mean
performance of the D:A:D and Framingham equations yielded AUROC of 0.894 (95% CI: 0.849, 0.940) and 0.877 (95% CI: 0.823,
0.932), respectively. The Framingham equation over-predicted DM events compared to D:A:D for lower glucose and lower
triglycerides, and for BMI levels below 25 kg/m2.
Conclusions: The D:A:D equation performed well in predicting the short-term onset of DM in the validation dataset and for
specific subgroups provided better estimates of DM risk than the Framingham.
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Introduction
HIV-positive patients receiving combination antiretroviral
therapy (cART) frequently experience metabolic complica-
tions such as dyslipidemia and insulin resistance, as well as
lipodystrophy, increasing the risk of cardiovascular disease
(CVD) and diabetes mellitus (DM) [1,2]. Rates of DM
and other glucose-associated disorders among HIV-positive
patients have been reported to range between 2 and 14%
[36]. In an ageing HIV-positive population who are also
on cART, the prevalence of DM is expected to continue to
increase. Risk factors for DM in the general population, such
as older age, male sex, obesity, lowered high density lipo-
protein cholesterol (HDL-C) and raised total cholesterol, have
also been found to contribute to the risk of DM in the
HIV-positive population [710]. Additional factors in HIV-
positive patients include lipodystrophy and immunosuppres-
sion [8,11], as well as antiretroviral therapy, though the role
of antiretroviral therapy remains less clear. An increased risk
of DM has been found to be associated with protease
inhibitors (PIs) [2,8,12,13] and individual nucleoside reverse
transcriptase inhibitors (NRTIs), principally the thymidine
analogues [7,1417], while tenofovir, abacavir and non-
nucleoiside reversetranscriptase (NNRTIs) have not been
associated with DM risk [7,8,11,17]. The Data Collection on
Adverse Events of Anti-HIV Drugs (D:A:D) study has shown a
significant association between new onset DM and exposure
to cART, an effect driven mainly by exposure to thymidine
analogues [7].
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Models for predicting the risk of DM over a five- to ten-
year period have previously been developed in the general
population [1820]. These models have included reasonably
routinely available patient data such as age, sex, weight,
glucose, blood pressure, HDL-C, triglycerides, parental dia-
betes and receipt of medications. A model based on more
complex clinical markers did not predict more accurately than
models based on more routine measurements [19]. However,
the ability of these DM prediction models to accurately
predict the risk of DM in an HIV-positive population is not
well known. Furthermore, as diagnosed HIV-positive patients
are under routine clinical care, many of these DM risk factors
are routinely collected on an ongoing (at least annual) basis
[21]; given that current treatment guidelines also recom-
mend metabolic assessment at least annually [21,22], inter-
vention in this population may occur much earlier. In such
instances, a model investigating the risk of DM over a shorter
period of three to six months (i.e. over the average period
between consecutive clinic visits) for patients under active
follow-up would more accurately reflect the manner in
which HIV-positive patients are followed than one predicting
risk five to ten years into the future. A risk equation for
CVD in HIV-positive patients, using similar short-term time-
varying methodology, has recently been developed by our
group [23].
The objective of this current analysis is to develop a
model to predict the risk of DM in HIV-positive popula-
tions over a short-term period (six months) and to compare
this to existing models previously developed in the general
population.
Methods
The D:A:D study is a prospective, multi-cohort observational
collaborative study, including 11 previously established
cohorts following 33,308 patients at 212 clinics from Europe,
Argentina, Australia and the United States. The primary
objective of the D:A:D study is to investigate the possible
association between cART and the risk of myocardial
infarction (MI). The study methodology has been described
in detail previously [24]. Briefly, patients were under active
follow-up at the individual cohorts at the time of enrolment
into the D:A:D study and were included irrespective of
whether or how long they were receiving antiretroviral
treatment (ART). As part of their routine clinical care data
were collected, which include demographic and other pro-
spective patient characteristics such as age, sex, body mass
index (BMI) (calculated based on height and weight), CVD,
DM, family history of coronary heart disease (CHD), cigarette
smoking, blood pressure therapy, DM therapy, lipid lowering
and antihypertensive therapy and serum lipid levels (total
cholesterol, HDL-C and triglycerides including information
on whether values were fasting measures), as well as HIV-
related core clinical data including ART medication received,
CD4 cell count, viral load and all clinical AIDS diagnoses.
Definition of DM
DM is a protocol-defined D:A:D secondary endpoint, and
all prospective documented cases were verified by the
completion of a D:A:D event monitoring case report form.
New onset diabetes was defined as either definite, if there
was a documented fasting plasma glucose of]7.0 mmol/L
(126 mg/dL) measured on two or more consecutive occa-
sions, or possible, if the patient was recorded as being dia-
betic with a reported date of onset, and was known to have
initiated anti-diabetic therapy. Both definite and possible
DM cases were analyzed.
Statistical methods
The current analyses include all patients recruited to the
D:A:D study with follow-up data, without prior DM, MI or
other CVD events and with a complete DM risk factor profile.
Baseline was defined as the first time point at or after
inclusion to the D:A:D study when all DM risk factors were
present. Restricting the dataset to patients with a complete
risk factor profile allowed for the direct comparison of
the D:A:D prediction model with the Framingham model (see
‘‘Assessing the performance of the risk equation’’ below).
However, a further analysis was also performed including
data on all D:A:D participants, with missing data coded using
missing value categories, to assess whether the predictive
accuracy of the models altered. Follow-up time was from
baseline to the date of new onset DM, death, 1 February
2010 or six months after the patient’s last clinic visit, which-
ever occurred first.
Poisson regression methods were used to determine
the factors associated with the short-term (six month) risk
of new onset DM in the complete dataset (the development
dataset). The predictive model was fitted using time-updated
covariates for all laboratory parameters. Although this ap-
proach is not generally used when developing prognostic risk
equations, it was considered more appropriate in our study
for two reasons. First, HIV-positive patients, particularly
those on treatment, are routinely seen by their clinicians,
at least three or six monthly intervals. Second, over the
calendar period the D:A:D study covers, the management
of DM and CVD has evolved and improved considerably.
A short-term risk equation, therefore, is better placed to
accommodate the changes in patient management that have
occurred over this period.
Risk factors assessed included the conventional risk factors
for DM such as age, sex, fasting and non-fasting glucose
(a non-fasting glucose7.8mmol/L was considered as the
equivalent to a fasting value of5.6 mmol/L) [25], blood
pressure (categorized as high: systolic]130 or diastolic
]85; or receiving blood pressure lowering therapy, and
low: systolicB130 and diastolicB85), HDL-C (low:B1.034
mmol/L; median:]1.034 toB1.550; and high:]1.550
mmol/L), LDL-C (low:B2.584; median:]2.584 toB3.359;
high:]3.359 mmol/L), triglycerides (normal:B1.693 mmol/
L; borderline to high:]1.693 toB2.257mmol/L; high:
]2.257 toB5.643; very high:]5.643) (lipid cut-offs based
on ATP III guidelines [26]), BMI per kg/m2 and family history
of CHD. As a possible alternative to triglycerides and HDL-C
as individual measures, the triglyceride to HDL-C ratio was
also assessed. However, to avoid over-fitting, only those vari-
ables with the best fit in univariate analyses, as determined
by the log-likelihood ratio, were assessed in multivariate
analyses. In this instance, triglycerides and HDL-C as individual
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measures performed better in univariate analyses compared
with the triglyceride to HDL-C ratio.
In previous analyses smoking was associated with a re-
duced risk of DM [7,27]. The mechanism for this is unclear,
and so to ensure generalizability of results, smoking was
not considered as a covariate in these analyses. Subsequent
exploratory analyses including smoking did not improve
predictions appreciably (data not shown).
The following HIV-related covariates were also assessed:
mode of HIV exposure, duration since first HIV-positive test,
prior AIDS-defining illness, CD4 cell count, HIV viral load,
lipodystrophy and duration of exposure to cART and to each
class of drugs. Individual ARTs were also assessed, but limited
to those previously determined in the D:A:D study to be
significantly predictive of DM (stavudine, zidovudine and
didanosine) [7]. Finally, hepatitis C (HCV) and B (HBV) status
were also assessed as potential DM risk factors.
All variables were fitted as time-updated covariates
(modelling time-updated variables allows for assessment of
the short-term risk of new onset DM), while only sex and
HIV exposure category were fixed. Lipid parameters, BMI
and CD4 cell count were all assessed as continuous as well as
categorical covariates; all, apart from BMI, fitted better
as categorical rather than continuous. The independent
predictors of new onset DM were determined using back-
ward model selection methods. All covariates that were
significant at pB0.1 in univariate analyses were considered
in the multivariate model, and only factors significant at
pB0.05 in the multivariate model were included in the final
predictive model.
Assessing the performance of the risk equation
The performance of the D:A:D risk equation was assessed
using the internal-external cross-validation (IECV) method
[28]. Briefly, this approach fits the prognostic model using
a leave-one-out cross-validation approach. If there are k
cohorts, then the model is fitted on a k-1 pooled cohort.
The performance of the model is then assessed on the cohort
that was excluded [29]. Of the 11 cohorts who participate in
the D:A:D study, nine cohorts reported all the DM risk factors
specified earlier and, therefore, were included in these
analyses. Of the nine cohorts, five cohorts reported 20 or
more events of DM and were excluded one at a time from the
pooled cohort dataset. A further four cohorts each reported
fewer than 20 events and were subsequently combined to
create the final cohort to be excluded from the pooled
dataset. In total, five pooled datasets were created, and
the prognostic model was fitted to these datasets one at a
time and subsequently assessed for performance on the
excluded cohort. Performance was measured as area under
the receiver operating characteristic (AUROC) curve, and a
weighted average of the five AUROC’s was then determined.
The discrimination and accuracy of the equation was
also compared with the performance of the Framingham
Offspring Study DM equation. We chose the simple clinical
model (the model with obesity defined by BMI only) as
several of the data for the more complex models are not
routinely collected in D:A:D (such as two hour oral glucose
tolerance test and fasting insulin levels). Expected eight-year
probabilities were determined based on the Framingham
algorithm and then converted to a prediction over the
shorter D:A:D follow-up period using a linear model. While
the Framingham equation might be expected to order
patient risk accurately, it might well not be expected to
predict the absolute risk accurately. This was previously
demonstrated by D’Agostino et al. 2001 [30], showing the
Framingham equation systematically over-estimating the
risk of CHD, although the ordering of the risk was similar
[30]. The complete dataset was therefore used to recalibrate
the Framingham equation, essentially by increasing the
constant terms in the model so that the total number of
DM events predicted in the training dataset was equal
to the observed number. The Framingham model was
also assessed using the aforementioned cross-validation
approach, and a weighted average AUROC for this model
was also determined.
The AUROC analysis was used to assess the discrimination
of the D:A:D study and Framingham risk scores [31], while
the accuracy of the risk scores was assessed by comparing
the observed versus the predicted number of events for
specific subgroups (these were limited to covariates pre-
dictive of DM that are in both the D:A:D and Framingham
algorithms). The D:A:D risk score was also used to estimate
the proportions that were at low (B1%), moderate (1 to
5%), high (5 to 10%) and very high risk (10%) for DM over
a two- and five-year period. The absolute two- and five- year
risk was calculated by applying the D:A:D DM risk equation
to each individual from the start of their follow-up.
Results
Of the 33,308 patients followed in the D:A:D study, 16,632
(50%) had a complete DM risk factor profile, with 376 cases
of new onset DM during 89,469 PY; the median follow-
up was 5.2 years (IQR: 3.0 to 8.1). The incidence of DM
in this analyzed population was 4.2 per 1000 PY). Patient
characteristics are summarized in Table 1.
The predictive model
In initial univariate analyses, increased time since AIDS
diagnosis and smoking were counter intuitively associated
with a decreased risk of DM and were excluded from any
further consideration. Triglycerides were also found to be
much more predictive than the triglyceride:HDL ratio; hence,
the ratio was also not considered further.
Factors that were identified as independently predictive
of new onset DM included the following: glucose levels
more than 5.6 mmol/L for fasting measures or more than
7.8 mmol/L for non-fasting measure (pB0.001), increasing
BMI (pB0.001), high triglycerides (pB0.001) and increasing
age per five years (pB0.001). Among the HIV covariates
increasing CD4 category (p-trend0.001) and lipodystrophy
(pB0.001) were also independently predictive of new onset
DM (Table 2). Male gender, increasing total cholesterol, lower
HDL-C category, higher systolic or diastolic blood pressure or
receiving blood pressure treatment, a prior AIDS diagnosis,
any PI use and cumulative use of stavudine were significant
in univariate analyses but did not remain significant in
multivariate analyses.
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Performance of the D:A:D and Framingham risk equations
From the IECV process, the D:A:D risk equation yielded a
weighted average AUROC of 0.894 (95% CI:0.849, 0.940),
while the recalibrated Framingham algorithm yielded a
weighted average AUROC of 0.877 (95% CI: 0.823, 0.932).
Observed and predicted numbers of new onset DM events
for the D:A:D and the recalibrated Framingham risk equations
by key patient subgroups (factors common in both the
Framingham and D:A:D risk equations) are summarized in
Table 3. The Framingham equation predicted 258.5 new
onset DM events in the complete dataset and was recali-
brated to predict the observed 376. As might be expected,
the D:A:D equation fitted marginal subgroup totals better
than the recalibrated Framingham equation. The Framingham
algorithm over-predicted DM events compared to the D:A:D
model for those with lower glucose (219 and 146 events,
respectively, compared with the observed 141 events), lower
triglycerides (116 and 87 events, respectively, versus an
observed 84 events), and slightly lower for those with BMI
levels between 26 and 29 (80 and 95 events compared with
an observed 107 events) and BMI above 30 kg/m2 (52 and
60 events compared with an observed 60 events).
The absolute two- and five-year risk is shown in Table 4.
Two and six percent of the study population was estimated
to be at high risk, and less than 1% and 4% at very high
risk, of developing DM over two and five years, respectively.
These proportions were considerably lower among females
compared to males, and among younger (B40 years) com-
pared to older individuals.
We also developed a DM prediction model excluding
glucose, the key predictor in both the D:A:D and Framingham
models, essentially to identify HIV-positive patients who
might be at raised risk of DM and who subsequently should
have a fasting glucose assessment to allow more accurate
prediction. This model included many of the same covariates
identified in the full model previously discussed, such as age,
BMI, triglycerides and CD4 cell count. In addition, this model
also included HDL-C and blood pressure. As with the model
Table 1. Patient characteristics at baseline
No diabetes Diabetes Total
No. of subjects 16,256 376 16,632
Median follow up (years) 5.3 2.5 5.2
Time at risk (person-years) 88385.3 1083.5 89468.8
Median (IQR)
Age (years) 46.1 (40.9 to 52.4) 48.1 (41.8 to 55.5) 46.2 (40.9 to 52.5)
Cumulative cART exposure (years) 2.8 (0.6 to 5.4) 2.9 (1.0 to 4.4) 2.8 (0.6 to 5.3)
Cumulative PI exposure (years) 1.8 (0 to 3.8) 2.0 (0.1 to 3.7) 1.8 (0 to 3.8)
CD4 count (cells/mL) 469 (310 to 665) 432 (271 to 665) 468 (308 to 665)
HIV-RNA (copies/mL) 50 (50 to 2400) 50 (50 to 2240) 50 (50 to 2394)
HDL-C (mmol/L) 1.170 (0.940 to 1.460) 1.037 (0.852 to 1.296) 1.164 (0.931 to 1.457)
Triglycerides (mmol/L) 1.569 (1.027 to 2.490) 2.418 (1.520 to 3.905) 1.580 (1.030 to 2.510)
Trig:HDL-C ratio 1.34 (0.78 to 2.45) 2.41 (1.33 to 4.43) 1.36 (0.78 to 2.49)
Systolic blood pressure 120 (110 to 130) 130 (120 to 140) 120 (110 to 130)
Diastolic blood pressure 80 (70 to 81) 80 (73 to 86) 80 (70 to 82)
BMI (kg/m2) 22.9 (20.9 to 25.2) 25.0 (22.8 to 27.9) 23.0 (20.9 to 25.3)
Number (%)
Female 27.3 14.9 4498 (27.0)
Current cigarette smoker 51.6 45.0 8151 (51.5)
Ex-smoker 17.9 17.1 2834 (17.9)
Transmission group
Heterosexual 33.9 35.1 5647 (33.9)
Homosexual 40.9 38.8 6790 (40.8)
Person who injects drugs 19.6 19.7 3261 (19.6)
Other 5.6 6.4 934 (5.6)
Ethnicity
White 60.6 62.5 10,089 (60.7)
Non-white 7.0 6.6 1157 (7.0)
Other 2.3 1.3 386 (2.3)
Unknown 30.1 29.5 5000 (30.1)
Prior AIDS 24.2 29.0 4036 (24.3)
Hepatitis C positive 27.1 24.9 4156 (25.0)
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including glucose, male gender, increasing total cholesterol,
prior AIDS diagnosis, any PI use and cumulative D4T use were
not included in the final model. The mean weighted average
AUROC for this model was 0.756 (95% CI: 0.737 to 0.775).
Finally, in the sensitivity analysis, where all D:A:D patients
with missing data were included using missing data cate-
gories, the weighted average AUROC for the D:A:D equation
was 0.847 (95% CI: 0.780 to 0.914).
Table 2. Final predictive models in the complete dataset
Full model Model without glucose
IRR 95% CI p p IRR 95% CI p p
Age per five years 1.16 1.10 1.21 B0.001 1.19 1.13 1.25 B0.001
Glucose category (mmol/L)
Less than 7.8 (non-fasting)/5.6 (fasting)
Greater or equal 7.8 (non-fasting)/5.6
(fasting)
12.89 10.43 15.92 B0.001    
Triglycerides (mmol/L)
Normal (B1.693)
Borderline to high (]1.693 toB2.257) 1.87 1.34 2.60 B0.001 B0.001 1.87 1.34 2.62 B0.001 B0.001
High (]2.257 to B5.643) 2.91 2.23 3.79 B0.001 2.88 2.19 3.79 B0.001
Very High (5.643) 5.91 4.23 8.27 B0.001 6.47 4.57 9.16 B0.001
BMI (per kg/m2) 1.10 1.08 1.13 B0.001 1.13 1.10 1.15 B0.001
CD4B200 cells/mL
CD4]200 toB350 cells/mL 0.52 0.36 0.77 0.001 B0.001 0.49 0.33 0.72 B0.001 B0.001
CD4]350 cells/mL 0.51 0.37 0.69 B0.001 0.48 0.35 0.66 B0.001
Lipodystrophy 1.27 1.02 1.56 0.029
HDL-C (mmol/L)
Low (B1.034)
Median (]1.034 toB1.550)     0.77 0.62 0.96 0.021 0.017
High (1.550)     0.73 0.51 1.03 0.071
High BP (SYS]130 or DIA]85, or on BP
treatment)
    1.37 1.09 1.72 0.007
p values reported for test of homogeneity in nominal covariates and test for trend for ordinal covariates. Patients with data no recorded were
not included when testing trend. IRR, Incidence rate ratio.
Table 3. Observed versus predicted events
Predicted
Observed D:A:D Framingham recalibrated
Glucose category
Less than 7.8 (non-fasting)/5.6 (fasting) 141 146.4 219.1
Greater or equal 7.8 (non-fasting /5.6 (fasting) 235 229.6 156.9
Triglycerides (mmol/L)
Normal (B1.693) 84 86.5 116.5
Borderline to high (]1.693 toB2.257) 60 61.1 79.4
High (]5.257 toB5.643) 171 169.8 152.4
Very High (5.643) 61 58.5 27.7
BMI (kg/m2)
BMIB18 (underweight) 10 5.5 9.9
BMI]18 toB26 (normal weight) 199 217.8 234.4
BMI]26 toB30 (overweight) 107 93.1 80.0
BMI30 (obese) 60 59.6 51.8
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Discussion
We developed a short-term risk equation for the prediction
of new onset DM in a cohort of HIV-positive individuals.
Our risk equation included traditional DM risk factors age,
impaired glucose, and triglycerides as well as HIV-related
factors, HIV immunosuppression and the presence of lipodys-
trophy. To our knowledge, this is the first diabetes risk
equation using routinely collected clinical data developed
specifically for HIV-positive patients. This risk equation was
found to be relatively robust with good discrimination
when assessed by IECV methods and, as might be expected,
was also shown to have better overall performance and
discrimination to the Framingham risk equation.
Among the conventional risk factors, one notable excep-
tion in the D:A:D risk equation is male gender. Despite gender
being identified as an independent predictor of new onset
DM in a previous D:A:D analysis [7], it is not included in
the final D:A:D risk equation. The discrepancy between our
current analyses and prior D:A:D findings may largely be
explained by the smaller overall population included in
this analysis, almost half of that in previous D:A:D study.
Furthermore, the previous D:A:D analysis did not adjust for
lipids. Data from the Swiss HIV Cohort Study (SHCS) also
reported male gender as significant predictor of new onset
DM, yet similar to the previous D:A:D analyses, it did not
adjust for lipids [32]. Both the D:A:D study and the SHCS
reported risk ratio of 1.6 and 1.7, somewhat larger than our
current analyses of 1.1.
Among the HIV-related factors previously reported to be
significantly predictive of new onset DM not included in
our final risk equation model is antiretroviral treatment.
Cumulative stavudine and any PI use were significant in
univariate analyses but dropped out of the final model.
Several studies, including D:A:D previously, have reported
significant increased risk of DM with ART use. Previously
shown in the D:A:D study was an increased risk of DM with
NRTI use, specifically stavudine, zidovudine and didanosine,
and a decreased risk with ritonavir and nevirapine [7]. How-
ever, data from the MACS cohort reported an increased risk
of DM with ritonavir and saquinvar and a decreased risk with
indinavir and nelfinavir [12]. Given the ongoing debate and
inconsistency in associations of ART use and DM onset across
different populations, excluding ART treatment from a risk
equation for HIV-positive patients may in fact improve the
robustness of the equation and allows the current equation
to be used into the future where patterns of ART use will
continue to evolve.
Hepatitis C co-infection has also been shown in some
studies [12,33], but not all studies [8], to be associated with
DM. In our current analysis, we did not find HCV to be a
predictor of new onset DM. Studies that have reported an
association also report substantially greater incidence of DM.
In the Multi-Centre AIDS Cohort Study (MACS), DM incidence
ranged from 47 per 1000 PY for those receiving cART and
17 per 1000 PY in those not on cART [12]. Rates in our study
were much lower than MACS, 4.2 per 1000 PY similar to that
reported in the SHCS, who also did not find an association
between HCV and DM [8].
Performance
The D:A:D risk equation performed marginally better than
the Framingham equation, both overall, in terms of dis-
criminating between key subgroups such as those defined
by glucose, triglyceride levels and, to a lesser extent, BMI.
Nevertheless, the recalibrated Framingham also performed
well. The fact that the D:A:D analyses identified several of
the same predictors as the Framingham model is reassuring,
suggesting that key parameters, such as glucose and tri-
glycerides, may be interpreted qualitatively similarly in HIV-
positive populations as negative populations. However, we
were unable to compare the D:A:D model with other
established DM risk equations as the necessary data are
not routinely collected in the D:A:D study [18,20,34] 
thus, it remains uncertain how these models would per-
form in HIV-positive populations compared with either the
Framingham or the D:A:D equation.
There are some limitations to our analyses. First, we
included non-fasting as well as fasting glucose measures,
Table 4. DM two- and five-year risk stratification
Low Moderate High Very High
B1% 1 to 5% 5 to 10% 10%
Two-year risk
% of population 79.13 17.78 2.25 0.84
% of men 75.78 20.40 2.80 1.02
% of women 88.17 10.72 0.76 0.36
% of younger individuals (B40 yr) 88.63 10.46 0.80 0.12
% of older individuals (40 yr) 70.76 24.23 3.53 1.48
Five-year risk
% of population 54.37 35.25 6.13 4.25
% of men 48.13 39.54 7.21 5.12
% of women 71.19 23.68 3.22 1.91
% of younger individuals (B40 yr) 69.63 25.90 3.07 1.40
% of older individuals (40 yr) 40.91 43.49 8.83 6.76
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although accepted cut-offs for non-fasting glucose measures
were applied [25]. Second, family history of CVD was used
as a surrogate for family history of DM as this information is
not available in the D:A:D study. Third, we do not have data
on other factors previously identified as predictive of DM,
including waist circumference. Race has also been associated
with DM in both HIV and non-HIV studies [7,18] and has
been included in at least one DM risk model [18]. We were
unable to assess race in the present model as a substantial
proportion of the events occurred in the unknown race cate-
gory, as many of the collaborating cohorts do not routinely
report race. Exclusion of race in the D:A:D model, however,
makes our risk score more generalizable across HIV cohorts
from various regions and ethnic backgrounds. Finally, in order
to compare the D:A:D prediction model with the Framingham
model, we included only patients who had data for all
the pre-defined risk factors. Consequently, half of the
D:A:D cohort were excluded from the main analyses. If these
patients had differed considerably from the patients in-
cluded in the analyses, the generalizability of the prediction
equation may have been affected. However, the sensitivity
analysis which included the entire D:A:D cohort yielded a
very similar AUROC to the main analysis, demonstrating the
robustness of the equation.
A key strength of our equation is that it predicts the
short-term risk of DM, including variables that vary over time.
First, this short-term nature reflects the way HIV-positive
patients are managed, with regular clinic visits. Second, as
early intervention is possible, changes in management fit
better with this equation. Prediction of DM is also important
in HIV-positive cohorts because, as well as being a notable
condition in its own right, DM is also associated with the
development of more serious outcomes, in particular CVD
[23,35].
Application
Prevention and management of DM is becoming increasingly
important as HIV-positive people in the era of effective ART
are living longer, and the prevalence of DM is expected to
continue to increase. The D:A:D DM risk equation may be
used in a clinical setting by doctors treating HIV-positive
patients. The automatic calculation of the patient’s short-
term risk for DM would be beneficial in identifying more
efficiently patients at risk of developing DM and subse-
quently other CVDs. Current guidelines recommend meta-
bolic assessment among HIV patients when commencing
ART, at time of switching therapy, and at three to six months
after commencing or switching ART and once yearly during
stable therapy [21,22]. Assessment of the short-term risk of
new onset DM, therefore, may also occur with very little
additional inconvenience to the patient. The model without
glucose may also be used to screen patients and identify
those who are at very low risk of DM and therefore do
not require more frequent screening for glucose. Both pre-
diction models (with and without glucose) will be made
publicly available on the D:A:D website (http://www.cphiv.
dk/) and can be used for individual patients. While predic-
tions are only a guide and should not be over interpreted,
they do allow for patients at high risk to be identified, and
appropriate interventions may then be applied. Calculating
an individuals predicted risk is desribed in the appendix.
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Appendix
The risk of DM is estimated as:
1  exp (H*t); where
H ¼ expb0þb1x1þb2x2þb3x3þb4x4þb5x5þb6x6þb7x7þb8x8þb9x9
b010.176
b1x10.144 per 5 years of age (e.g. if age40 then
b1x1((40/5)*0.144)
b2x22.556 (x21 if glucose 7.8 non-fasting/5.6 fasting,
x20 if not)
b3x30.623 (x31 if TRIG]1.693 toB2.257 mmol/L,
x30 if not)
b4x41.069 (x41 if TRIG]2.257 toB5.643 mmol/L,
x40 if not)
b5x51.777 (x51 if TRIG5.643 mmol/L, x50 if not)
b6x60.098 per unit increase of BMI (e.g. if BMI25 then
b6x6(25*0.165)
b7x70.646 (x71 if CD]4200 to B350 cells/mL, x70
if not)
b8x80.677 (x81 if CD4]350 cells/mL, x80 if not)
b9x90.236 (x91 if lipodystrophy present, x90 if not)
Data in the D:A:D study are set up in monthly time units
(0.085 years); the above equation therefore produces a
monthly probability of developing DM. A reasonably good
approximation for calculating the estimated probability of
DM over longer time periods, t, is to multiply ‘‘H’’ by t years,
and use aget/2 in the equation. More exact computation
will be available through a calculator on the D:A:D website
(http://www.cphiv.dk/).
Worked example:
Consider an individual is male, 48.7 years of age, has fasting
glucose of 5.6 mmol/L, BMI of 27.5, triglyceride measure
of 2.65 mmol/L, CD4 cell count of 550 cell/ml, and with
lipodystrophy
To calculate the six month estimated risk of DM, we first
calculate:
b1x1calculated as 0.144*((48.70.25)/5), b2x22.556,
b3x30, b4x41.069, b5x50, b6x60.098*27.5, b7x70,
b8x80.677, b9x90.236.
Then H*t0.5*0.05560.0278
Therefore, the converted six month hazard (i.e. six month risk
of DM)2.74 per 1000 PY.
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